Project Grant R37CA295658
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$683K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
This federal Project Grant award of $402,728 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop innovative interpretable deep learning models for multi-modality imaging in cancer prognostic assessment, with a focus on improving the accuracy and interpretability of prognosis predictions for gastric cancer patients. The funded research project at Wake Forest University Health Sciences will integrate domain knowledge from physician...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...
The federal Project Grant award, totaling $384,342.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute For Cancer Research, a non-profit organization in New York, NY. The award, effective June 15, 2024 through June 14, 2027, supports the development of generalizable and reliable AI for early detection of melanoma. Through this funding, the Sloan-Kettering Institute For Cancer Research will...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has awarded a $693,156 Project Grant (CFDA 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health) to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop artificial intelligence (AI) algorithms for predicting prognosis and optimizing treatment selection for cutaneous squamous cell carcinoma (CSCC), a highly prevalent form of skin cancer. The project aims to train and validate AI...
This $593,383 Project Grant, awarded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The primary awardee, The Methodist Hospital Research Institute, is collaborating with The Johns Hopkins University on this project. The proposed system aims to eliminate...